Nanostructured Lipid Carriers Overcome the Low Immunogenicity of M2e Peptide via Surface Click Chemistry Conjugation, Improving the Anti-M2e Antibody Response
Louis Bourlon, Carole Fournier, Antoine Hoang, Christine Charrat, Alban Lepetitcolin, Jessica Morlieras, Fabrice Navarro, Patrice N. Marche
{"title":"Nanostructured Lipid Carriers Overcome the Low Immunogenicity of M2e Peptide via Surface Click Chemistry Conjugation, Improving the Anti-M2e Antibody Response","authors":"Louis Bourlon, Carole Fournier, Antoine Hoang, Christine Charrat, Alban Lepetitcolin, Jessica Morlieras, Fabrice Navarro, Patrice N. Marche","doi":"10.1002/anbr.202500236","DOIUrl":null,"url":null,"abstract":"<p>Influenza vaccines targeting hemagglutinin require annual updates due to viral variability, limiting protection against pandemic strains. The conserved matrix protein 2 ectodomain (M2e) peptide offers cross-strain immunity but suffers from low immunogenicity. Here, M2e peptides are conjugated onto nanostructured lipid carriers (NLCs) using bioorthogonal click chemistry, preserving key epitopes and enhancing antigen presentation. Immunization in mice demonstrates that NLC-M2e induces focused and robust anti-M2e antibody responses, which are significantly amplified by incorporating a pan-DR epitope helper T cell epitope, achieving antibody levels compatible with protection. The formulation elicits balanced IgG subclasses and T-helper 1 cell-type cellular responses, supporting effective immune mechanisms. These findings suggest that NLC-based delivery of M2e peptides, especially with helper epitopes, represents a promising universal influenza vaccine strategy warranting further preclinical and clinical investigation.</p>","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"6 4","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2026-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202500236","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Nanobiomed Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/anbr.202500236","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Influenza vaccines targeting hemagglutinin require annual updates due to viral variability, limiting protection against pandemic strains. The conserved matrix protein 2 ectodomain (M2e) peptide offers cross-strain immunity but suffers from low immunogenicity. Here, M2e peptides are conjugated onto nanostructured lipid carriers (NLCs) using bioorthogonal click chemistry, preserving key epitopes and enhancing antigen presentation. Immunization in mice demonstrates that NLC-M2e induces focused and robust anti-M2e antibody responses, which are significantly amplified by incorporating a pan-DR epitope helper T cell epitope, achieving antibody levels compatible with protection. The formulation elicits balanced IgG subclasses and T-helper 1 cell-type cellular responses, supporting effective immune mechanisms. These findings suggest that NLC-based delivery of M2e peptides, especially with helper epitopes, represents a promising universal influenza vaccine strategy warranting further preclinical and clinical investigation.
期刊介绍：
Advanced NanoBiomed Research will provide an Open Access home for cutting-edge nanomedicine, bioengineering and biomaterials research aimed at improving human health. The journal will capture a broad spectrum of research from increasingly multi- and interdisciplinary fields of the traditional areas of biomedicine, bioengineering and health-related materials science as well as precision and personalized medicine, drug delivery, and artificial intelligence-driven health science.
The scope of Advanced NanoBiomed Research will cover the following key subject areas:
▪ Nanomedicine and nanotechnology, with applications in drug and gene delivery, diagnostics, theranostics, photothermal and photodynamic therapy and multimodal imaging.
▪ Biomaterials, including hydrogels, 2D materials, biopolymers, composites, biodegradable materials, biohybrids and biomimetics (such as artificial cells, exosomes and extracellular vesicles), as well as all organic and inorganic materials for biomedical applications.
▪ Biointerfaces, such as anti-microbial surfaces and coatings, as well as interfaces for cellular engineering, immunoengineering and 3D cell culture.
▪ Biofabrication including (bio)inks and technologies, towards generation of functional tissues and organs.
▪ Tissue engineering and regenerative medicine, including scaffolds and scaffold-free approaches, for bone, ligament, muscle, skin, neural, cardiac tissue engineering and tissue vascularization.
▪ Devices for healthcare applications, disease modelling and treatment, such as diagnostics, lab-on-a-chip, organs-on-a-chip, bioMEMS, bioelectronics, wearables, actuators, soft robotics, and intelligent drug delivery systems.
with a strong focus on applications of these fields, from bench-to-bedside, for treatment of all diseases and disorders, such as infectious, autoimmune, cardiovascular and metabolic diseases, neurological disorders and cancer; including pharmacology and toxicology studies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
